|
IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment. |
|
|
|
Consulting or Advisory Role - Celgene/Jazz |
Research Funding - Amgen (Inst); BerGenBio (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst) |
Patents, Royalties, Other Intellectual Property - part of a patent for a TFR-2 antibody (Rauner et al. Nature Metabolics 2019) |
Travel, Accommodations, Expenses - Celgene |
|
|
Stock and Other Ownership Interests - Abbvie |
Consulting or Advisory Role - Abbvie; Acceleron Pharma; Bristol-Myers Squibb; Geron; Jazz Pharmaceuticals; Novartis |
Speakers' Bureau - Agios; Bristol-Myers Squibb; Jazz Pharmaceuticals |
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Jazz Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Acceleron Pharma; Agios; Astellas Pharma; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Cardinal Health; Celgene; Daiichi Sankyo; Epizyme; Incyte; Ionis Pharmaceuticals; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer; Seagen; Taiho Pharmaceutical; Takeda; Trovagene |
Consulting or Advisory Role - Abbvie; Acceleron Pharma; Agios; Astellas Pharma; BeyondSpring Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Cardinal Health; Celgene; Daiichi Sankyo; Epizyme; Incyte; Ionis Pharmaceuticals; Jazz Pharmaceuticals; Novartis; Otsuka; Pfizer; Seagen; Taiho Pharmaceutical; Takeda; Trovagene |
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); Aprea AB (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); Trovagene (Inst) |
Travel, Accommodations, Expenses - Celgene; Novartis; Pfizer; Trovagene |
|
|
Consulting or Advisory Role - Celgene; Millennium; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Takeda (Inst) |
|
|
Stock and Other Ownership Interests - Karyopharm Therapeutics |
Research Funding - ALX Oncology; Astex Pharmaceuticals; Incyte; TG Therapeutics |
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Celgene; Incyte; Ryvu Therapeutics; Sierra Oncology; TG Therapeutics |
|
|
Honoraria - Geron; Stemline Therapeutics |
Consulting or Advisory Role - Geron; Stemline Therapeutics |
|
|
Employment - Geron; Janssen |
Stock and Other Ownership Interests - Geron; Janssen |
|
|
|
Stock and Other Ownership Interests - Geron |
|
|
|
Stock and Other Ownership Interests - Geron; Johnson & Johnson; Moderna Therapeutics |
Travel, Accommodations, Expenses - Geron |
|
|
Stock and Other Ownership Interests - Bristol-Myers Squibb; Geron; Johnson & Johnson |
|
|
|
Stock and Other Ownership Interests - Geron |
|
|
|
Stock and Other Ownership Interests - Geron; Johnson and Johnson |
|
|
|
Stock and Other Ownership Interests - Geron |
|
|
Employment - Geron; Janssen |
Stock and Other Ownership Interests - Geron; Janssen |
Travel, Accommodations, Expenses - Geron; Geron; Janssen |
|
|
Honoraria - Celgene/Bristol-Myers Squibb; Janssen-Cilag; Novartis |
Consulting or Advisory Role - Celgene/Bristol-Myers Squibb; Geron; Gilead Sciences; Gilead Sciences; Menarini; Novartis; Pfizer; Takeda |
Research Funding - Celgene (Inst) |
Travel, Accommodations, Expenses - Celgene; Janssen-Cilag |